NeoPUTTY®与NeoMTA 2®作为第一磨牙髓切开术药物:一项随机临床试验

IF 1.5 4区 医学 Q3 DENTISTRY, ORAL SURGERY & MEDICINE
Pediatric dentistry Pub Date : 2023-05-15
Abeer S Alqahtani, Nohair N Alsuhaibani, Ayman M Sulimany, Omar A Bawazir
{"title":"NeoPUTTY®与NeoMTA 2®作为第一磨牙髓切开术药物:一项随机临床试验","authors":"Abeer S Alqahtani,&nbsp;Nohair N Alsuhaibani,&nbsp;Ayman M Sulimany,&nbsp;Omar A Bawazir","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this randomized clinical trial was to evaluate the clinical and radiographic success of the premixed bioceramic (NeoPUTTY®) as pulpotomy medicament in primary molars in comparison to NeoMTA® 2.</p><p><strong>Methods: </strong>Seventy primary molars indicated for pulpotomy in 42 children were randomly allocated into two groups: (1) a mineral trioxide aggregate (MTA) group (NeoMTA® 2); and (2) a premixed bioceramic group (NeoPUTTY®). Clinical and radiographic examinations of the molars following pulpotomy were conducted by two independent evaluators at six and 12 months. The data were analyzed using Fishe`s exact tests.</p><p><strong>Results: </strong>At 12 months, the clinical and radiographic success for the MTA group were 100 percent (34 out of 34) and 94.1 percent (32 out of 34), respectively. For the NeoPUTTY® group, the clinical and radiographic success were 97.1 percent (34 out of 35) and 92.8 percent (32 out of 35), respectively. No significant differences were found between the two materials.</p><p><strong>Conclusions: </strong>NeoPUTTY® showed a comparable success to mineral trioxide aggregate in primary molar pulpotomies over 12 months. Further clinical trials with larger sample sizes and longer follow-up periods are recommended.</p>","PeriodicalId":19863,"journal":{"name":"Pediatric dentistry","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2023-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"NeoPUTTY<sup>®</sup> Versus NeoMTA 2<sup>®</sup> as a Pulpotomy Medicament for Primary Molars: A Randomized Clinical Trial.\",\"authors\":\"Abeer S Alqahtani,&nbsp;Nohair N Alsuhaibani,&nbsp;Ayman M Sulimany,&nbsp;Omar A Bawazir\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>The purpose of this randomized clinical trial was to evaluate the clinical and radiographic success of the premixed bioceramic (NeoPUTTY®) as pulpotomy medicament in primary molars in comparison to NeoMTA® 2.</p><p><strong>Methods: </strong>Seventy primary molars indicated for pulpotomy in 42 children were randomly allocated into two groups: (1) a mineral trioxide aggregate (MTA) group (NeoMTA® 2); and (2) a premixed bioceramic group (NeoPUTTY®). Clinical and radiographic examinations of the molars following pulpotomy were conducted by two independent evaluators at six and 12 months. The data were analyzed using Fishe`s exact tests.</p><p><strong>Results: </strong>At 12 months, the clinical and radiographic success for the MTA group were 100 percent (34 out of 34) and 94.1 percent (32 out of 34), respectively. For the NeoPUTTY® group, the clinical and radiographic success were 97.1 percent (34 out of 35) and 92.8 percent (32 out of 35), respectively. No significant differences were found between the two materials.</p><p><strong>Conclusions: </strong>NeoPUTTY® showed a comparable success to mineral trioxide aggregate in primary molar pulpotomies over 12 months. Further clinical trials with larger sample sizes and longer follow-up periods are recommended.</p>\",\"PeriodicalId\":19863,\"journal\":{\"name\":\"Pediatric dentistry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2023-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric dentistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DENTISTRY, ORAL SURGERY & MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric dentistry","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
引用次数: 0

摘要

目的:这项随机临床试验的目的是评估预混生物陶瓷(NeoPUTTY®)作为初级磨牙髓切开术药物与NeoMTA®2相比的临床和放射学成功。方法:将42例患儿70颗牙髓切开术的乳牙随机分为两组:(1)三氧化二矿骨料(MTA)组(NeoMTA®2);(2)预混生物陶瓷基团(NeoPUTTY®)。在6个月和12个月时,由两名独立的评估人员对牙髓切开术后的磨牙进行临床和影像学检查。使用fisher的精确测试对数据进行了分析。结果:在12个月时,MTA组的临床和影像学成功率分别为100%(34 / 34)和94.1%(34 / 32)。对于NeoPUTTY®组,临床和放射学成功率分别为97.1%(35人中34人)和92.8%(35人中32人)。两种材料之间没有发现显著差异。结论:NeoPUTTY®在12个月的初级磨牙切齿手术中显示出与三氧化二矿骨料相当的成功。建议进一步进行更大样本量和更长的随访期的临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
NeoPUTTY® Versus NeoMTA 2® as a Pulpotomy Medicament for Primary Molars: A Randomized Clinical Trial.

Purpose: The purpose of this randomized clinical trial was to evaluate the clinical and radiographic success of the premixed bioceramic (NeoPUTTY®) as pulpotomy medicament in primary molars in comparison to NeoMTA® 2.

Methods: Seventy primary molars indicated for pulpotomy in 42 children were randomly allocated into two groups: (1) a mineral trioxide aggregate (MTA) group (NeoMTA® 2); and (2) a premixed bioceramic group (NeoPUTTY®). Clinical and radiographic examinations of the molars following pulpotomy were conducted by two independent evaluators at six and 12 months. The data were analyzed using Fishe`s exact tests.

Results: At 12 months, the clinical and radiographic success for the MTA group were 100 percent (34 out of 34) and 94.1 percent (32 out of 34), respectively. For the NeoPUTTY® group, the clinical and radiographic success were 97.1 percent (34 out of 35) and 92.8 percent (32 out of 35), respectively. No significant differences were found between the two materials.

Conclusions: NeoPUTTY® showed a comparable success to mineral trioxide aggregate in primary molar pulpotomies over 12 months. Further clinical trials with larger sample sizes and longer follow-up periods are recommended.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pediatric dentistry
Pediatric dentistry DENTISTRY, ORAL SURGERY & MEDICINEPEDIATRI-PEDIATRICS
CiteScore
1.20
自引率
6.20%
发文量
74
审稿时长
>12 weeks
期刊介绍: Pediatric Dentistry is the official publication of the American Academy of Pediatric Dentistry, the American Board of Pediatric Dentistry and the College of Diplomates of the American Board of Pediatric Dentistry. It is published bi-monthly and is internationally recognized as the leading journal in the area of pediatric dentistry. The journal promotes the practice, education and research specifically related to the specialty of pediatric dentistry. This peer-reviewed journal features scientific articles, case reports and abstracts of current pediatric dental research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信